AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.
- ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
- These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
- “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
- The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.